Want to see TSE:OTC full AI Analyst Report?

Ocumetics Technology Corp (OTC) Price & Analysis

26 Followers

OTC Stock Chart & Stats

C$0.52

-C$0.05(-9.62%)

At close: Jul 27 4:00 PM EDT

C$0.52

-C$0.05(-9.62%)

Day’s Range― - ―

52-Week RangeC$0.35 - C$1.99

Previous CloseN/A

Volume8.89K

Average Volume (3M)77.99K

Market Cap

C$63.80M

Enterprise ValueC$37.05M

Total Cash (Recent Filing)C$436.82K

Total Debt (Recent Filing)C$5.70M

Price to Earnings (P/E)―

Beta0.71

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding141,782,420

10 Day Avg. Volume70,232

30 Day Avg. Volume77,988

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)-18.65

Price to Sales (P/S)0.00

P/FCF Ratio-21.06

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Ophthalmic Product LineA dedicated IOL program focuses R&D and regulatory effort on a single, high-value device category. That specialization supports deeper technical expertise, a clearer clinical/regulatory pathway, and the potential for durable commercial adoption if trials and approvals succeed.

Intellectual Property And Commercialization PlanningActive IP development plus explicit regulatory and commercialization planning indicate management is building structural barriers and a go-to-market blueprint. Strong IP and a defined regulatory strategy increase long-term licensing, partnership, or market exclusivity potential.

Lean Organizational StructureA very small workforce implies a lean cost base and potentially capital-efficient R&D operations. For a development-stage medtech firm, low fixed overhead can extend runway per financing round and allow focused deployment of scarce resources toward validation milestones.

Bears Say

No RevenueZero reported revenue confirms the company is pre-commercial and dependent on successful product development and regulatory approvals for any durable cash generation. This elevates execution risk and means near-term performance hinges entirely on future milestones rather than existing sales.

Growing Net LossesMaterial and accelerating losses erode capital and force recurring external funding needs. Over a multi-month horizon this raises dilution or refinancing risk, constrains investment in clinical/commercial scaling, and pressures management to secure capital rather than solely focus on product execution.

Weak Balance Sheet And Rising DebtSteeply higher leverage and negative equity materially reduce financial flexibility and increase insolvency risk. This structural weakness raises the cost of capital, limits ability to fund trials or commercialization internally, and heightens dependence on dilutive or expensive external financing.

Ocumetics Technology Corp News

Ocumetics Advances First-in-Human Lens Trials After Productive ASCRS Meetings

An announcement from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp., a Canadian developer...

4M ago

Ocumetics to Court Strategic Partners as First-In-Human Lens Data Debuts at ASCRS

Ocumetics Technology Corp ( ($TSE:OTC) ) just unveiled an announcement. Ocumetics Technology Corp., a Canadian ophthalmic technology developer,...

5M ago

Ocumetics Unveils Streamlined Breakthrough Design for Next-Generation Intraocular Lens

Ocumetics Technology Corp ( ($TSE:OTC) ) has shared an update. Ocumetics Technology Corp. announced major design breakthroughs in...

5M ago

Ocumetics Grants Stock Options to IR Advisor as It Advances Novel Intraocular Lens

An update from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp., a Canadian ophthalmic...

5M ago

Ocumetics forms scientific advisory committee to steer late-stage development of accommodating intraocular lens

Ocumetics Technology Corp ( ($TSE:OTC) ) just unveiled an announcement. Ocumetics Technology Corp., a developer of next-generation ophthalmic...

6M ago

Ocumetics Adds Capital Markets Veteran to Board as It Advances Novel Intraocular Lens

Ocumetics Technology Corp ( ($TSE:OTC) ) has issued an announcement. Ocumetics Technology Corp., a Canadian developer of advanced...

6M ago

Ocumetics Extends Debenture Forbearance and Closes $1.02 Million LIFE Financing

Ocumetics Technology Corp ( ($TSE:OTC) ) has issued an announcement. Ocumetics Technology Corp. has secured a forbearance agreement...

6M ago

Ocumetics De-Risks Accommodating Lens Platform With Strong First-in-Human Results

Ocumetics Technology Corp ( ($TSE:OTC) ) has shared an announcement. Ocumetics Technology Corp. reported positive three-month postoperative results...

7M ago

Ocumetics Seeks Debenture Forbearance and Warrant Incentive to Extend $4 Million Financing

An announcement from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp. has proposed a...

7M ago

Ocumetics Replaces Chief Medical Officer Role With Scientific Advisory Committee Ahead of Pivotal Trial

Ocumetics Technology Corp ( ($TSE:OTC) ) just unveiled an announcement. Ocumetics Technology Corp., a leader in next-generation ophthalmic...

7M ago

OTC FAQ

What was Ocumetics Technology Corp’s price range in the past 12 months?

Ocumetics Technology Corp lowest stock price was C$0.35 and its highest was C$1.99 in the past 12 months.

What is Ocumetics Technology Corp’s market cap?

Ocumetics Technology Corp’s market cap is C$63.80M.

When is Ocumetics Technology Corp’s upcoming earnings report date?

Ocumetics Technology Corp’s upcoming earnings report date is Sep 01, 2026 which is in 14 days.

How were Ocumetics Technology Corp’s earnings last quarter?

Currently, no data Available

Is Ocumetics Technology Corp overvalued?

According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ocumetics Technology Corp pay dividends?

Ocumetics Technology Corp does not currently pay dividends.

What is Ocumetics Technology Corp’s EPS estimate?

Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ocumetics Technology Corp have?

Ocumetics Technology Corp has 141,782,420 shares outstanding.

What happened to Ocumetics Technology Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Ocumetics Technology Corp?

Currently, no hedge funds are holding shares in TSE:OTC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ocumetics Technology Corp

Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.